NAD+ (Direct)

The downside is driven less by acute danger than by cost, effort, and the opportunity cost of a better-evidenced alternative. Direct NAD+ has no intrinsic life-threatening signal, and it clears quickly, so reversibility is excellent and dependency is essentially nil. The heavier weights come from the IV-clinic burden: several hundred to over 1000 dollars per infusion, hours in a chair, repeated visits, and a sterility and sourcing risk that lives in the route rather than the molecule. The single biggest opportunity cost is that the oral precursors do the same NAD-raising job with real human trials and a fraction of the price, so money and time spent on the drip is money not spent on the better-supported option.

Safety Risk (2.4/5.0): Direct NAD+ is generally safe with no intrinsic life-threatening signal, since it is an endogenous molecule, but it carries real route-specific hazards. The defining adverse experience is rate-dependent infusion discomfort, flushing, nausea, abdominal or chest tightness, and lightheadedness, which is why infusions run slowly over hours, as the published study did, per Grant 2019. Those reactions are transient and resolve when the rate drops. The larger concern is not NAD+ the molecule but IV and injection therapy itself: line infection, phlebitis, and especially compounding and sterility risk, because most direct-NAD+ products are grey-market or research chemicals rather than approved sterile pharmaceuticals. There is also no large controlled safety database, so the profile is inferred from physiology and clinic use, not from trial pharmacovigilance. Absence of a catastrophic signal is not the same as documented safety.

Side Effect Profile (2.8/5.0): Side effects are common but transient and rate-dependent. The signature complaint is the drip itself feeling bad when run fast: flushing, nausea, chest pressure, and an urge to slow it down, all consistent with the slow 6-hour infusion used in the one human study, per Grant 2019. Slow the rate and the discomfort eases. Beyond that, subcutaneous and intranasal routes can cause local irritation. None of this is dangerous at standard practice, but the predictable in-session discomfort is the everyday cost users describe most.

Financial Cost (3.6/5.0): Cost is a genuine drag and the IV-clinic model makes it worse. A single IV NAD+ infusion commonly runs several hundred to over 1000 dollars, and because the molecule is rapidly catabolized and excreted, per Grant 2019, one session produces only transient changes, so clinics sell multi-infusion courses and loading protocols. An addiction detox course of daily infusions can stack into thousands of dollars over a week. The at-home routes are cheaper per dose but trade verified, sterile product for research-chemical material of unknown quality. Set against oral precursors that cost a small fraction and carry actual human data, the recurring spend on an unproven direct-administration benefit is heavy financial exposure.

Time/Effort Burden (3.6/5.0): Effort is high relative to a supplement, and the IV-clinic burden is the core of it. IV NAD+ means booking and traveling to a clinic, getting a line placed, and sitting through an infusion that runs for hours rather than minutes specifically to keep flushing and nausea in check, per the slow 6-hour protocol in Grant 2019. Because a single session is transient, any sustained effect means repeating that whole visit. The at-home subcutaneous, sublingual, and intranasal routes trade the chair for self-injection or daily self-dosing of material whose purity and sterility you cannot verify. Either path dwarfs the effort of swallowing a precursor capsule with breakfast.

Opportunity Cost (3.2/5.0): Opportunity cost is the most important downside here, because a better-evidenced path to the same goal exists. The oral precursors raise blood NAD+ in human trials and cost a fraction of an IV course, so the rational way to chase higher NAD+ is usually NMN or NR, with the related cofactor Ca-AKG in the same conversation. Money and hours spent on infusions whose intact cellular uptake is contested could go to those cheaper, better-supported options or to sleep, training, and diet that move the same outcomes with far more certainty.

Dependency/Withdrawal (2.0/5.0): Dependency risk is low. NAD+ is an endogenous molecule and there is no physiologic dependence or withdrawal syndrome from infusions. Any reliance is functional, the effect simply fades when you stop, rather than a tolerance or rebound problem. The pattern of repeated visits is driven by transience and marketing, not by a hooked physiology.

Reversibility (1.8/5.0): Reversibility is excellent, one of the few clean wins. Infused NAD+ is rapidly metabolized and excreted, per Grant 2019, so it clears quickly and any unwanted effect passes once the infusion stops. There is no lasting change to undo and no taper required. This low score reflects a genuine strength: nothing about direct NAD+ leaves a durable mark, for better or worse.